Provectus Biopharmaceuticals Expands Global Patent Portfolio for Active Pharmaceutical Ingredient Manufacture

Tuesday June 19, 2018

KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus today announced that the Indian Patent Office (IPO) has granted the Company's patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which is Provectus' lead investigational oncology drug. The Company's patent estate associated with API manufacturing provides intellectual property protection in a number of countries in Asia, Europe, and North America into the 2030s.

IPO patent 297453 is linked to U.S. patent (USP) 8,530,675, entitled "Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenzofuran-1,9-xanthen]-3-one (Rose Bengal) and Related Xanthenes," which was awarded by the United States Patent and Trademark Office (USPTO) in 2013. The Company received related awards from, among others, the European Patent Office (EPO), the Japan Patent Office (JPO), and the State Intellectual Property Office (SIPO or the Chinese Patent Office) in 2015.

Continuations of Provectus' foundational manufacturing patent include USP 9,273,022 and USP 9,422,260, which were awarded by the USPTO in 2016.

Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (Provectus or the Company) is a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers in adults and children.

About PV-10

Provectus’ lead investigational oncology drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.

About Provectus

Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).

Contact:

Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.
President
Phone: 866-594-5999

NEWSLETTER
Errors